trending Market Intelligence /marketintelligence/en/news-insights/trending/i5yrzwirbugrz4opd8udqg2 content esgSubNav
In This List

Myovant names chief commercial officer, makes board changes

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Myovant names chief commercial officer, makes board changes

Myovant Sciences Ltd. named Kim Sablich chief commercial officer.

Sablich was GlaxoSmithKline PLC's vice president of primary care marketing in the U.S.

Myovant also added Myrtle Potter, Mark Guinan and Frank Torti to its board of directors.

Potter, who is the operating chair at Roivant Sciences Ltd.'s Roivant Pharma division, was also named chairman of the Myovant board.

Guinan is CFO and executive vice president at Quest Diagnostics Inc.

Torti is vant investment chair at Roivant Pharma.

London-based Myovant develops therapies for women's health and endocrine diseases.